CANTOS: landmark study, modest benefits—more research needed

  • Anil Pareek
  • Indranil Purkait
  • Ravi Mehta
  • Kumar Naidu
Letter to the Editor
  • 4 Downloads

Notes

Authors’ contributions

All authors have contributed equally to the manuscript.

Compliance with ethical standards

Conflict of interest

Authors are affiliated to Ipca Laboratories Limited and are involved in research studies on anti-diabetic drugs.

References

  1. 1.
    Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.Google Scholar
  2. 2.
    Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48.Google Scholar
  3. 3.
    Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19(6):27.CrossRefPubMedGoogle Scholar
  4. 4.
    Maiorino MI, Bellastella G, Giugliano D, Esposito K. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? Endocrine. 2017 Feb;55(2):360–5.CrossRefPubMedGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2018

Authors and Affiliations

  1. 1.Medical Affairs and Clinical ResearchIpca Laboratories LimitedMumbaiIndia
  2. 2.Medical AffairsIpca Laboratories LimitedMumbaiIndia
  3. 3.Clinical Research and DevelopmentIpca Laboratories LimitedMumbaiIndia

Personalised recommendations